Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial

The efficacy of convalescent plasma for coronavirus disease 2019 (COVID-19) is unclear. Although most randomized controlled trials have shown negative results, uncontrolled studies have suggested that the antibody content could influence patient outcomes. We conducted an open-label, randomized contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bégin, Philippe, Callum, Jeannie, Jamula, Erin, Cook, Richard, Heddle, Nancy M., Tinmouth, Alan, Zeller, Michelle P., Beaudoin-Bussières, Guillaume, Amorim, Luiz, Bazin, Renée, Loftsgard, Kent Cadogan, Carl, Richard, Chassé, Michaël, Cushing, Melissa M., Daneman, Nick, Devine, Dana V., Dumaresq, Jeannot, Fergusson, Dean A., Gabe, Caroline, Glesby, Marshall J., Li, Na, Liu, Yang, McGeer, Allison, Robitaille, Nancy, Sachais, Bruce S., Scales, Damon C., Schwartz, Lisa, Shehata, Nadine, Turgeon, Alexis F., Wood, Heidi, Zarychanski, Ryan, Finzi, Andrés, Arnold, Donald M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604729/
https://www.ncbi.nlm.nih.gov/pubmed/34504336
http://dx.doi.org/10.1038/s41591-021-01488-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604729/
https://www.ncbi.nlm.nih.gov/pubmed/34504336
http://dx.doi.org/10.1038/s41591-021-01488-2

Ejemplares similares